IndustryCompany release

Protagonist reports Q3 results as MIMRYLO approval triggers $275M in Takeda payments

🇺🇸 Protagonist Therapeutics, Inc (PTGX) · Thu 05 Nov 2026

Protagonist Therapeutics says the FDA's August approval of rusfertide for polycythemia vera drove milestone income, while icotrokinra gained approvals in China, Japan and the EU.

Protagonist Therapeutics reported its third-quarter 2026 results on 5 November, highlighting the US approval of MIMRYLO (rusfertide), developed with partner Takeda. The US Food and Drug Administration approved the product on 28 August for erythrocytosis in adults with polycythemia vera.

According to the company, the approval triggered payments of $275 million from Takeda.

Protagonist also noted progress for ICOTYDE (icotrokinra) in psoriasis, which has now gained approvals in China, Japan and the European Union.

On the balance sheet, the company reported $834.6 million in cash and announced a $300 million share buyback. The summary available to VigiEye does not include further detail on revenue, earnings or the terms of the repurchase.

What it means for your team

  • Regulatory teams tracking polycythemia vera now have a US-approved rusfertide product, MIMRYLO, to reference for erythrocytosis in adults.
  • Icotrokinra's approvals in China, Japan and the EU mark a widening of ex-US market access for ICOTYDE in psoriasis.
  • Market-access teams should watch for pricing, reimbursement and launch details, which were not included in the information available.

Company's press release (SEC filing): Protagonist Therapeutics, Inc ↗

Article written by VigiEye from the official source (Protagonist Therapeutics, Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →